news releases
-
Apr 9, 2019Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has dosed the first...
-
Apr 2, 2019Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas...
-
Mar 28, 2019Dr. Bluestone is a World-renowned Expert and Academic Leader in Immune Tolerance Research
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jeffrey...
-
Mar 19, 2019Plan to Initiate PROTECT Study for PRV-031 (teplizumab) in T1D Patients in Q2
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth...
-
Mar 12, 2019
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...
-
Feb 13, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
-
Jan 28, 2019Provention is currently developing PRV-101 as a polyvalent vaccine for acute coxsackie virus infection and to potentially prevent the onset of T1D
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
-
Jan 3, 2019Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
-
Nov 28, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...
-
Nov 8, 2018Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
Q3 2018 and Recent Corporate Highlights: Completed $63.9 million upsized initial public offering Announced co-development agreement with Amgen and in-licensing of PRV-015 (Amgen's AMG-714), a...
-
Nov 5, 2018Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
THOUSAND OAKS, Calif. and OLDWICK, N.J. – (Nov. 5, 2018) – Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated...
-
Nov 1, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...
-
Oct 23, 2018- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, announced today that it has completed enrollment in the Phase 1b clinical trial...
-
Sep 11, 2018
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today its Chief Executive Officer...
-
Sep 5, 2018Industry executive adds considerable financial expertise as audit committee chairperson
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Avery (Chip) W....
-
Aug 13, 2018
Recent Corporate Highlights: Closed initial public offering of common stock on July 19, 2018, generating $63.9 million in gross proceeds Expanded pipeline with two additional clinical-stage assets...
-
Jul 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Mark Rigby, MD,...
-
Jul 19, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public...
-
May 9, 2018-- Provention acquires PRV-031 (teplizumab) and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
May 7, 2018- Coxsackievirus B appears to be an important trigger for type 1 diabetes
Provention Bio, Inc. (Provention), a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...
-
Sep 28, 2017-- Andrew Drechsler Named Chief Financial Officer
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
Sep 21, 2017- Provention to initiate Phase 2a Study of PRV-6527 (JNJ-40346527) in patients with moderate to severe Crohn's disease
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
Jul 18, 2017- Enterovirus vaccine platform in-licensed from Vactech Oy will be developed to "pre-empt" type 1 diabetes by targeting coxsackievirus B infection
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
Jul 11, 2017Accomplished Biopharmaceutical and Drug Development Executive to Spearhead Provention's Vision of Intercepting and Preventing Immune-mediated Disease
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
Jun 26, 2017Industry innovators, Francisco Leon, MD, Ph.D. and Ashleigh Palmer, cofound newly established company
Provention Bio, Inc., a recently founded clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...